# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for...
Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key compe...
Guggenheim analyst Vamil Divan maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $14 to $13.
Strong immune response after third yearly booster dose in children and adultsSignificant anamnestic antibody response across al...
HC Wainwright & Co. analyst Brandon Folkes reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $18 price target.